Significant Revenue Growth
Year-over-year revenue increased by 128% in the fiscal second quarter, reaching $1.8 million, up from $0.8 million during the same period last year.
Expansion of Global Footprint
Added new distribution partnerships in Japan, South Korea, Mexico, Costa Rica, Guatemala, Panama, and El Salvador, broadening international coverage to 35 countries.
Financial Stability
Raised $12 million in debt and secured a $20 million equity line of credit with Streeterville Capital, solidifying the balance sheet for future growth and Gen II launch.
Operational Improvements
Reduced total operating expenses by 37% year-over-year and achieved a substantial decrease in net cash burn by 66% compared to the previous year.
Positive Clinical Trial Updates
Beyond Cancer's Phase Ia trial showed promising survival rates, with a median survival of 22 months, and positive interim results for LungFit PH in neonatal ECMO gas circuit.